Literature DB >> 2292200

Structure and function of high endothelial postcapillary venules in lymphocyte circulation.

P P De Bruyn, Y Cho.   

Abstract

Mesh:

Year:  1990        PMID: 2292200     DOI: 10.1007/978-3-642-75519-4_4

Source DB:  PubMed          Journal:  Curr Top Pathol        ISSN: 0070-2188


× No keyword cloud information.
  6 in total

1.  Statins inhibit lymphocyte homing to peripheral lymph nodes.

Authors:  René Schramm; Michael D Menger; Yves Harder; Rudolf Schmits; Oliver Adam; Gabriele Weitz-Schmidt; Hans-Joachim Schäfers
Journal:  Immunology       Date:  2006-11-28       Impact factor: 7.397

2.  Molecular mechanisms of lymphocyte homing to peripheral lymph nodes.

Authors:  R A Warnock; S Askari; E C Butcher; U H von Andrian
Journal:  J Exp Med       Date:  1998-01-19       Impact factor: 14.307

Review 3.  Lymph node pathology in primary combined immunodeficiency diseases.

Authors:  F Facchetti; L Blanzuoli; M Ungari; O Alebardi; W Vermi
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1.

Authors:  L Zanotti; R Angioni; B Calì; C Soldani; C Ploia; F Moalli; M Gargesha; G D'Amico; S Elliman; G Tedeschi; E Maffioli; A Negri; S Zacchigna; A Sarukhan; J V Stein; A Viola
Journal:  Leukemia       Date:  2016-02-22       Impact factor: 11.528

5.  L-selectin-mediated leukocyte adhesion in vivo: microvillous distribution determines tethering efficiency, but not rolling velocity.

Authors:  J V Stein; G Cheng; B M Stockton; B P Fors; E C Butcher; U H von Andrian
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

6.  A novel endothelial L-selectin ligand activity in lymph node medulla that is regulated by alpha(1,3)-fucosyltransferase-IV.

Authors:  Christine M'Rini; Guiying Cheng; Colleen Schweitzer; Lois L Cavanagh; Roger T Palframan; Thorsten R Mempel; Richard A Warnock; John B Lowe; Elizabeth J Quackenbush; Ulrich H von Andrian
Journal:  J Exp Med       Date:  2003-11-03       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.